{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-24-000039","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.232502+00:00","generated_at":"2026-05-31T14:02:59.170500+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zymeworks Q2 2024 net loss $69.3M; cash $395.9M; zanidatamab BLA priority review by Nov 29","bullets":["Net loss for H1 2024: $69.3M vs $75.5M loss in H1 2023; revenue $29.3M (down from $42.6M).","Cash, equivalents and marketable securities $395.9M as of June 30, 2024; runway into 2H 2027.","FDA granted Priority Review for zanidatamab BLA in 2L HER2+ BTC; PDUFA date Nov 29, 2024.","Discontinued zanidatamab zovodotin (ZW49) to focus on ZW171 and ZW191 Phase 1 starts in 2H 2024.","Appointed Leone Patterson as EVP, Chief Business Officer and CFO, effective Sep 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-24-000039","json":"https://secwatch.observer/filing/0001937653-24-000039.json","markdown":"https://secwatch.observer/filing/0001937653-24-000039.md","text":"https://secwatch.observer/filing/0001937653-24-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765324000039/0001937653-24-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765324000039/zyme-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:02:59.170500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}